Home > Drugs A – Z > Boceprevir (By mouth)

Boceprevir (By mouth)

Treats hepatitis C. Used together with peginterferon alpha and ribavirin.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Boceprevir is used in combination with injectable peginterferon alfa (Pegasys®, Pegintron®) and ribavirin (Copegus®, Rebetol®) to treat chronic hepatitis C infection. These medicines are used in patients with compensated liver disease (including cirrhosis), who have not been treated before or who have received other medicines but did not work well. Boceprevir is a direct-acting antiviral agentRead more
Brand names include
Victrelis
Drug classes About this
Antiviral

What works? Research summarized

Evidence reviews

Boceprevir -- Benefit Assessment According to §35a Social Code Book V [Internet]

The benefit assessment of boceprevir was in accordance with the approved therapeutic indications and with the following research questions:

The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1

BACKGROUND: The licensing of direct-acting antivirals heralds a new era in the treatment of hepatitis C virus (HCV) genotype 1. We undertook a mixed treatment comparison to examine the relative efficacy among current treatments for HCV.

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis

BACKGROUND: The aim of this study was to examine the relative efficacy and safety of boceprevir and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using an indirect comparison meta-analysis.

See all (38)

Summaries for consumers

Treating Chronic Hepatitis C: A Review of the Research for Adults

This summary will discuss treatment options for chronic hepatitis C. It will tell you about research on how well medicines for chronic hepatitis C work. It will also tell you about research on the side effects of these medicines. It does not discuss screening and diagnosis of hepatitis C. This summary can help you talk with your doctor about which treatment might be best for you.

Ledipasvir / sofosbuvir (Harvoni) for chronic hepatitis C: Ledipasvir / sofosbuvir (Harvoni) for hepatitis C (genotype 1) in people without liver cirrhosis who have had no previous treatment

In early 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of ledipasvir / sofosbuvir compared with standard therapies for the treatment of hepatitis C infection. The following results apply to cases of chronic hepatitis C (genotype 1) in people without liver cirrhosis who have had no other previous treatment. The patients did not also have an HIV infection. For this group, IQWiG carried out a historical comparison with data from a total of nine studies. Three of these studies looked into treatment with ledipasvir / sofosbuvir and the other six examined the triple therapy with peginterferon alfa, ribavirin, and boceprevir or telaprevir.

Ledipasvir / sofosbuvir (Harvoni) for chronic hepatitis C: Ledipasvir / sofosbuvir (Harvoni) for hepatitis C (genotype 1) in people who have had previous treatment

In early 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of ledipasvir / sofosbuvir compared with standard therapies for the treatment of hepatitis C infection. The following results apply to cases of chronic hepatitis C infection in people who have had previous treatment. The patients did not also have an HIV infection. For this group, IQWiG performed a historical comparison with data from a total of nine studies. Five of these studies looked into treatment with ledipasvir / sofosbuvir and the other four examined the triple therapy with peginterferon alfa, ribavirin, and boceprevir or telaprevir.

See all (8)

PubMed Health Blog...

read all...